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Summary. Therapeutic cancer prevention is a new field that can learn a lot from the successes in the 
prevention of cardiovascular diseases. While weight control and physical activity are important for 
both, preventive therapies have much to add. Low dose aspirin for cancer prevention stands out as 
the most important agent in terms of population benefit, and should be offered to most people above 
the age of 50 years who do not have hypertension or risk factors for gastrointestinal bleeding. 
Universal vaccination against the human papillomavirus, ideally with the 9-valent vaccine, also offers 
clear benefits for the whole population if given before infection occurs (typically at age 12-14y). Other 
therapies, notably anti-oestrogen drugs for breast cancer prevention need to be targeted to high risk 
groups to maintain a favourable benefit-risk ratio. Better algorithms for their identification and better 
platforms for reaching them, eg. as part of a screening visit remain a key priorities if  the discoveries 
made to date are to have an important impact on public health. Many other promising agents have 
been identified, often as components of food, but negative experiences with beta-carotene and 




Introduction. Cancer prevention is a large field comprising lifestyle changes to reduce risk, 
screening interventions to detect early lesions and preventive interventions aimed at more 
actively interrupting the carcinogenic pathway. Here we only consider the later. Compared to 
cardiovascular disease where preventive treatments are firmly established, the development 
of therapies to prevent cancer is still in its infancy. This in part reflects the fact that cancers 
2 
 
are more heterogeneous and biologically complex than cardiovascular diseases, and causal 
pathways are less well understood. Good biomarkers for identifying individuals at increased 
risk for specific cancers are missing and even less is known about predictive factors for 
response to specific treatments.  
 
The balance of risks and benefis is also inherently more challenging for preventive than for 
therapeutic interventions. Only a small fraction of the apparently healthy people who receive 
a preventive treatment would develop the specific type of cancer being targeted and lack of 
cancer is not apparent at an individual level, whereas all will incur some risk of side effects 
which are identifiable on an individual basis. This also leads to challenges in evaluating new 
agents as trials need to be larger in order to have enough endpoints points, and also longer 
as preventive effects often take more time to appear, as early stages of the carcinogenic 
process are targeted. Fear of cancer also has a greater impact on the human psyche leading 
to unsupported claims and wishful expectations for preventive efficacy for a plethora of 
unproven agents.  
Here I review interventions for which there is good evidence of efficacy, those with promising 
but not fully convincing findings, and those for which there is a substantial amount of 
evidence of no benefit and in some cases even harm. Assessments are my subjective personal 
views based on the available data, but are not formal reviews such as those conducted by 
IARC, NICE or the USPSTF, which are only available for a limited number of agents. However, 





Surgery. Prophylactic surgery is an appropriate option for a small number of cases where the 
risk of disease (usually genetically based) is strong –   typically above 50%. There are two 
notable examples: colectomy for individuals with polyposis coli which is caused by a mutation 
in the apc gene and occurs in about 1 in 7000 to 23 000 people depending on the population¹,2. 
About 25-30% of these mutations are thought to be de novo with no affected family members. 
Surgery often takes place before age 25y at which time, a large number of polyps are already 
present, and is virtually 100% effective if undertaken before cancer is present. The other well-
known example is women with a mutation in the BRCA1 or BRCA2 gene, which gives rise to a 
greatly increased risk of breast cancer (about 60% lifetime risk) and ovarian cancer (55% for 
BRCA1 and 16·5% for BRCA2)3. Removal of the ovaries around age 35-40y is common for 
BRCA1 and up to 5 years later for BRCA2. It not only eliminates ovarian cancer but also 
reduces breast cancer risk by about half4, whereas bilateral mastectomy eliminates 90-95% 
of breast cancer risk5. There is increasing evidence that most ovarian cancers initially arise in 
the fallopian tubes and only removing them could prevent this disease, and would result in 
fewer side effects6. Mutation in other rare genes can also lead to consideration of 
prophylactic surgery, although it is important reserve this extreme option for the very highest 
risk women, as above as some of these mutations only carry at 20-30% lifetime risk. 
Vaccination. Vaccination against the human papilloma virus is likely to have a major impact 
on cervical and some other cancers. Vaccination before infection has been shown to virtually 
eliminate persistent infection and precursor cervical lesions (CIN) due to the HPV types 
contained in the vaccine, but longer follow up is needed before an effect on cancer becomes 
apparent.  Two vaccines have been widely used – Gardasil7 containing virus like particles 
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(VLPs) as antigens against HPV types 16 and 18, which cause cancer, as well as types 6 and 11 
which protect against genital warts. Cervarix8 only contains VLPs for types 16 and 18. Recently 
a new 9-valent HPV vaccine which contains VLPs against 31,33,45,52 and 58 as well as 6, 11, 
16 and 18 has shown very high efficacy against all 9 types if given before infection9.   
Infant vaccination against Hepatitis B in Taiwan, where it is the major causative factor for 
hepatocellular cancer, has led to a more than 60% reduction in this cancer below the age of 
20y10. The main reasons for failure were active infection in the mother and incomplete 
vaccination. Further follow up will be needed to see if this protection continues into 
adulthood. Preventing Hepatitis C induced cancer remains a major challenge, as no effective 
vaccine has yet to be developed11 although expensive treatments are now available to clear 
infections12. 
 
Pharmacologic Drugs initially used for other purposes.   
The greatest impact on the field of preventive therapy has been the use of drugs initially 
developed for other indications. This approach has been especially effective for demonstrating 
the preventive effect of anti-oestrogenic agents for breast cancer and aspirin for the 
gastrointestinal cancers, and is likely to lead to further important discoveries.  One further 
discovery is that oral contraceptives have been clearly shown to reduce the risk of ovarian 
cancer by 27% for ever use and more than 50% for 10 years or longer use13, although it is 




Breast cancer. Breast cancer prevention has been facilitated by the fact that drugs evaluated 
for their ability to prevent recurrence of a breast cancer also provide reliable evidence for a 
preventive effect on new tumours in the contralateral breast.  Table 1 shows a variety of agents 
that have been evaluated for primary prevention. 
Tamoxifen was the first such agent to illustrate this. Based on data from the CRC-II adjuvant trial, 
Cuzick and Baum14 published the first report of a preventive effect for tamoxifen.  A meta-analysis of 
20 randomized clinical trials of five-year treatment with tamoxifen as adjuvant therapy in 15 000 women 
documented an approximately one-third reduction in contralateral breast tumours15. Four prevention 
trials have subsequently confirmed this finding in high risk women without breast cancer (Table 1). 
Overall, these trials show a 38% reduction in breast cancer incidence16, resulting from a 50% reduction 
of oestrogen receptor positive breast cancers but no effect on oestrogen receptor negative tumours. 
These trials have shown that the protection from tamoxifen persists after stopping the medication. In 
fact, for the two trials with the longest follow up17,18, a greater reduction in breast cancer incidence was 
observed in the follow up period than during active treatment (cumulative risk 4·6% vs 6·3% in years 
0-10; 3·3% vs 6·3 % in years 10-20), and this has persisted for 15 years after treatment completion 
(Figure1).  
The two major side effects of tamoxifen are endometrial cancer and venous thromboembolism. (Table 
2). Endometrial cancer was increased by approximately 2·5 fold above the baseline rate of about 60 per 
100 000 per year at age 60, whereas venous thromboembolism was found about twice as often in the 
tamoxifen arm compared to placebo. Recent reports have shown that the excess of thromboembolic 
events is limited to the active treatment period, whereas the excess of endometrial cancer appears to 
continue after cessation. Less serious but more common side effects of tamoxifen include vasomotor 
symptoms such as hot flushes, night sweats and gynecologic symptoms such as bleeding and uterine 
polyps19.  Topical formulations of tamoxifen metabolites applied directly to the breast are now under 
study with the hope that the local does will be high enough to maintain its preventive effects, but the 
systemic dose will be reduced enough to limit its side effects84.  Tamoxifen  has now been approved for 
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use in breast cancer prevention for high risk women in the USA by FDA and recommended in the UK 
by NICE. 
Three other selective oestrogen receptor modulators (SERMs) have now been evaluated in addition to 
tamoxifen.  Raloxifene is a second generation SERM originally developed to prevent osteoporosis in 
postmenopausal women. It has oestrogenic effects on bone and lipid metabolism, and anti-estrogenic 
effects on the endometrium and breast tissue. Because of this tissue selectivity, raloxifene has fewer 
side effects than tamoxifen. Three trials have evaluated raloxifene as a preventive agent for breast 
cancer in postmenopausal women (Table 1) and all have shown efficacy.  In the MORE trial a 65% 
reduction in breast cancer was found after 4 years of treatment, which led to its continuation as the 
CORE trial with breast cancer as a primary endpoint20, where a 50% reduction in breast cancer was 
seen. A second study known as RUTH21 evaluated the impact of raloxifene in women with increased 
cardiovascular risk as the primary endpoint and found a 44% reduced incidence of invasive breast 
cancer.  
The STAR trial22 is the only randomized clinical trial that has directly compared raloxifene with 
tamoxifen. It found that the reduction in breast cancer risk from raloxifene was about 25% less than for 
tamoxifen.  In contrast to tamoxifen, no excess of endometrial cancer or other gynaecological problems 
were observed. However like tamoxifen it was associated with an increase of thromboembolic events, 
although the magnitude of the increase appears to be smaller. While raloxifene is less effective than 
tamoxifen, it may be more acceptable for postmenopausal women, where it is already widely used for 
osteoporosis.  Raloxifene has now been approved for use in breast cancer prevention for high risk 
postmenopausal women in the USA by FDA and recommended in the UK by NICE. 
Two other SERMs (lasofoxifene and arzoxifene) have been investigated in osteoporotic 
postmenopausal women with reduction in fractures as the primary endpoint. The PEARL trial23 
evaluated two doses of lasofoxifene vs placebo and based on 49 breast cancers incidence was 
significantly reduced by 79% with the higher 0·5 mg/day dose when compared to placebo. Furthermore, 
although there was a significant increase in thrombotic events, lasofoxifene significantly reduced major 
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coronary events, strokes and both vertebral and non-vertebral fractures and so it may be ideal for 
prevention, where the total benefit–harm balance is particularly important.  
The GENERATIONS trial24 evaluated arzoxifene (20 mg/day) versus placebo in 9,354 postmenopausal 
women with osteoporosis (Table 1). It reduced all breast cancer events by 58% and vertebral fractures 
by 41%, but increased the incidence of thromboembolic events, hot flushes, muscle cramps and 
gynecological events, as with other SERMs (except gynecologic events for raloxifene). 
 
Aromatase Inhibitors 
The third generation aromatase inhibitors (AI) anastrozole, letrozole and exemestane have been found 
to be more effective than tamoxifen for the treatment of oestrogen receptor positive breast cancer in 
postmenopausal women25 and are now routinely used for this indication. Contralateral breast tumours, 
a good surrogate for new cancers, were also reduced by a further 50% compared to tamoxifen in these 
trials26. 
Two large breast cancer prevention trials have reported on the use of AIs in high risk women without 
cancer. The MAP3 trial randomized 4560 postmenopausal women to receive either exemestane or 
placebo for 5 years. A 65% reduction of invasive breast cancers was seen27. No reduction was observed 
for ER-negative disease, but the effect on ER-positive disease was even greater (HR=0·27 (0·12-0·60), 
P<0·001). No statistically significant differences were found between treatment arms for adverse 
events, suggesting a good benefit-risk profile. However, these conclusions are limited by the short 
follow-up period of only 35 months.  
The IBIS-II trial compared anastrozole to placebo in postmenopausal women at increased risk of breast 
cancer28. After a median of 5 years of follow-up a highly significant 53% reduction of invasive breast 
cancer and DCIS combined (primary endpoint) was seen (HR = 0·47, 95% confidence interval (0·32-
0·68), P<0·0001), which was similar to the results reported in the MAP3 trial.  For oestrogen receptor 
positive invasive cancer the reduction was 58% (HR=0·42 (0·25-0·71), P<0·001), but as in the MAP3 
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trial no effect was found for ER-negative breast cancer. Vasomotor and musculoskeletal side effects 
were increased with anastrozole, but only by 10-15%, and these adverse events were also reported 
by many women receiving placebo.  Thus most of these events were not attributable to anastrozole, 
but reflect a high incidence of them for all women in their early postmenopausal years. This illustrates 
the need to have a placebo arm to accurately assess subjective side effects.  The risk of fractures was 
slightly but non-significantly increased by 11% (8·5% vs 7·7%) for anastrozole. This was much less than 
the 50% increase seen in a previous adjuvant trial29, mostly likely due to the use of bone density (DXA) 
scans at entry, and appropriate bisphosphonate prophylaxis for women with low bone density.  
Blinded long-term follow-up is continuing in IBIS-II, so that the long-term efficacy and side effects of 
anastrozole can be evaluated.  
Overall, the reported reductions in breast cancer incidence for both exemestane and anastrozole were 
larger than those seen for tamoxifen or raloxifene, and indicate that these two drugs are an attractive 
option for breast cancer prevention in postmenopausal women at increased risk of the disease. NICE 
have recently issued draft guidelines for consultation for the use of anastrozole in postmenopausal 
women in the UK (https://www.nice.org.uk/guidance/GID-NG10010/documents/short-version-of-
addendum). For premenopausal women the only current option remains tamoxifen.  
None of these anti-oestrogen agents have had any impact on oestrogen receptor negative breast 
cancer, which remains an unmet need.   
 
Aspirin and other NSAIDs 
There is now overwhelming evidence for an approximately one-third reduction in colorectal 
cancer incidence and mortality from long term regular aspirin use30. Beneficial effects of a 
similar size have been seen for oesophageal and gastric cancers,  and smaller, less convincing 
5-15% reductions for lung, breast  and prostate cancers (Table 1)  have also emerged over the 
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past several years28,31,32. There is also a suggestion of a small effect also for ovarian cancer, 
but this is still uncertain. There appears to be little or no effect on other major cancer sites 
including pancreatic, endometrial, and haematopoietic tumours. Long term use of about 10 
years was estimated to reduce overall cancer incidence by about 10% in men and 7% in women, 
and overall cancer mortality by 13% in men and 9% in women28. Gastrointestinal and cerebral 
bleeding are the most important harms associated with aspirin use, and their risk and fatality 
rate increase with age33. Use of prophylactic aspirin in the general population aged 50-65y is 
likely to be beneficial when the reduction in cancer and cardiovascular disease and excess 
bleeding are all considered. For example for 100 men aged 55y taking low dose aspirin for 10 
years, Cuzick et al28 estimated that over the next 15 years there would be 2·29 fewer cancers, 
myocardial infractions  and strokes and 0·49 more gastrointestinal bleeding events. For women 
the numbers were 1·32 and 0·25 resp. In terms of deaths in the next 20 years, for men there 
would be 1·60 fewer deaths from cancer and heart disease and 0·17 more from GI bleeds and 
strokes. For women these numbers were 0·82 and 0·11, resp. Both benefits and harms increase 
with age in men and women. Thus the benefit-risk ratio is highly favourable for the general 
population and is about 5:1 for serious events and at least 7:1 for deaths. This is likely to 
increase with further treatment duration and follow up. It is also clear that only a small 
proportion of the population will benefit and identifying which individuals are most likely to 
do so would allow treatment to be more focussed. 
 The effects of daily aspirin on cancer incidence are not apparent until at least 3 years after the 
start of use (Figure 2), with a relative incidence reduction after that time for all cancers of about 
24%34, and some benefits appear to be sustained for several years after treatment cessation in 
long-term users. Relative reductions in cancer incidence appear to be similar in men and 
women34, although data are less extensive for women, and men have a higher incidence of the 
cancers reduced by aspirin, leading to greater absolute reductions. Two trials of alternate day 
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use of 100mg - the Women’s Health Study (WHS)35 and the Physicians’ Health Study (PHS) 
did not show any cancer reduction within 10 years of follow-up,  although a 43% reduction in 
colorectal cancer after 10 years has been observed in the WHS35. No differences between low 
and standard doses of aspirin have been observed either for efficacy or side effects, but there 
are no direct comparisons. Higher doses above 325mg/day do not appear to confer additional 
benefit but do increase toxicities. 
The impact of aspirin on cancer mortality appears to be larger than for incidence36.  The 
mechanisms by which aspirin prevents cancer incidence and mortality are poorly understood. 
Rothwell et al30 suggested that the greater effect on mortality is due to a reduction in metastatic 
spread, possibly through a platelet mediated mechanism, with benefits both before and after 
the diagnosis of cancer37,38. Trials are underway to examine aspirin as an adjuvant treatment 
for individuals with colorectal, gastric, oesophageal, breast and prostate cancer39. A recent 
review by the US Preventive Services Task Force (USPSTF) has given limited support for a 
preventive effect of aspirin on colorectal cancer incidence and possibly mortality82.  
 
Data on other NSAIDs such as ibuprofen, sulindac or celecoxib are less extensive and there 
are no trials with long term follow up, except for studies of colorectal adenomas. However 
observational studies have found similar overall effects on cancer incidence40,41. 
 
Agents with preliminary evidence for cancer prevention 
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Evidence for a potential preventive effect comes from two main sources, with very different 
limitations and potential confounding factors. One source is epidemiologic cohort and case-
control studies. These have the advantage of looking at exposure in human populations, but 
can only establish an association between exposure and reduced disease incidence. 
Confounding of the association by other concomitant exposures, lifestyle or socioeconomic 
factors is a challenging issue, and randomised prevention trials offer the only certain protection 
against this.  While epidemiologic studies have provided some important leads, such as for 
aspirin and colorectal cancer, there are also some serious examples where epidemiologic 
studies have suggested a preventive effect which was later disproved in randomised trials are 
indicated below. 
The other approach which has generated or supported preventive effects is mechanistic 
laboratory studies. While understanding mechanisms is very important, the main limitation 
here is that tissue culture or animal models cannot fully reproduce the human environment, 
and there are several examples where convincing evidence of a mechanistic effect in the 
laboratory has not translated into a preventive effect in humans. 
Several compounds have demonstrated both epidemiologic and laboratory evidence for a 
preventive effect. Of these metformin, a drug used to treat type 2 diabetes, is among the most 
promising.  Early interest was sparked by a study using the UK General Practice Research 
Database42, suggesting a more than 50% reduction in breast cancer. That was followed by other 
studies from this resource suggesting reductions in ovarian cancer. However no other cancers 
were reduced. Concerns have been raised about potential confounding with diabetes and 
especially the other medications used for this condition43.  In an overview of 65 540 cancer 
cases in 47 studies of diabetic women, metformin was found to have a beneficial effect on a 
range of cancers leading to an overall 31% reduction in incidence and 34% reduction in 
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mortality44. Some of the concerns raised previously were addressed in this review and some of 
the differences appeared to be related to differences in BMI and time related factors (adjusted 
incidence reductions 18% and 10%, resp). Significant reductions were only seen for lung and 
liver cancer. This remains an active area of research and a range of mechanisms have been 
suggested for metformin’s action including activation of the AMPK pathway or a direct effect 
on the insulin levels via the liver45.  
There are a vast range of agents, many of which are food constituents or their derivatives, 
which have shown anti-cancer effects in laboratory systems but for which evidence in humans 
is lacking or very minimal. It is not possible to review them all here. The US National Cancer 
Institute has a long standing and active programme in evaluating such agents. They periodically 
publish a compendium of drugs undergoing evaluation as potential cancer-preventive agents46. 
Most of these are still being investigated in laboratory systems, but some are also undergoing 
early Phase 1 and Phase 2 studies47, where biomarkers are also being studied as early indicators 
of treatment response. 
 
Dietary components   
 
Many studies have suggested a protective effect of consumption of fruits and vegetables, with 
a stronger effect seen in vegetables48. Specific potential ingredients include sulphoraphane 
found in cruciferous vegetables49 and lycopene, which is particularly high in cooked tomatoes, 
but is also found in other fruits and vegetables. High tomato consumption was initially linked 
to reduced prostate cancer risk by Mills et al50. A recent overview found no overall effect but 
a suggestion it might protect against high grade or fatal disease51.  
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A number of spices have also been proposed to have protective effects52. Curcumin which 
comes from turmeric has been most studied, but there is still very limited human data for cancer 
prevention53. Of the many hundreds of other compounds54, resveratrol, which mostly comes 
from red wine and berries55,56, green tea polyphenols57, and  pomegranate58 have received much 
attention but again convincing human evidence of efficacy is lacking.  
The evidence for a role of vitamin D with or without calcium is very mixed but overall there is 
currently no compelling evidence that it has an effect on any cancer site either for incidence or 
mortality59,82. 
 
Agents that haven’t worked  
Epidemiologic and laboratory evidence suggested a potential anti-cancer effect of Vitamin A, 
beta carotene and their analogues60,61. Despite randomised evidence of a benefit of beta 
carotene, vitamin E, and selenium in a severely deficient population in Linxian, China62, 
subsequent studies in the West have been negative. Two large studies of beta carotene in heavy 
smokers and asbestos exposed workers63,64 found it actually lead to increases in the incidence 
of lung cancer and Omenn et al63 found an increase in all-cause mortality. In an overview of 
all randomised trials of β-carotene Druesne-Pecollo et al65 confirmed an increase in lung cancer 
incidence, and also found an increase in gastric cancer and no significant effect on other 
cancers, either individually or overall. 
 
Trials of vitamin E, and selenium, both of which were thought to have a beneficial effect on 
prostate cancer, have also been negative. In particular neither selenium nor vitamin E 
supplementation reduced the incidence of prostate cancer in the SELECT trial, in which 
prostate cancer was the primary endpoint. Klein et al66 reported that in 35 533 men with a PSA 
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of 4 ng/mL or less and a negative digital rectal examination, the incidence of prostate cancer 
increased by 17% with vitamin E supplementation. Other studies have not shown any effects 
of supplementation on the incidence of prostate cancer67, colorectal cancer68 or cause specific 
mortality69. 
The use of 5α-reductase inhibitors either for prevention or management of early prostate cancer 
has produced complex outcomes, with substantial reductions in low Gleason grade disease but 
an apparent increase in high grade cancers. The Prostate Cancer Prevention Trial (PCPT)70 
investigated finasteride in men with low PSA (≤3 mg/mL) and no evidence of disease. After 
18 years of follow-up, a 30% (95%CI 24-35%) reduction was observed in all prostate cancers 
based on  a  43% reduction in low Gleason grade tumours but a 17% increase in high  grade 
(Gleason 7 or higher)  cancers.   No impact on death from prostate cancer was seen. Similar 
results were reported in the REDUCE trial71, which assessed dutasteride, another 5α-reductase 
inhibitor, in a high-risk population of men with a PSA concentration between 2·5 ng/mL and 
10 ng/mL and a negative initial prostate biopsy. After 4 years of follow-up, a 23% reduction in 
overall prostate cancer incidence was reported compared with controls who received placebo, 
but there was no effect on cancers with Gleason score 7 or higher, and an increase in Gleason 
10 tumours. Although both drugs have a beneficial effects on benign prostatic disease, the 
apparent increase in risk of high-grade tumours is of major concern. It has been suggested that 
this may be a result of detection bias. An increase in the sampling accuracy of the prostate with 
the then common six-needle biopsy, because of smaller total prostate size after 5α-reductase 
inhibitor therapy, has been offered as an explanation for this finding. Overall the evidence for 
a detrimental or protective effect on the incidence of high grade prostate cancer or prostate 
cancer specific site-specific mortality remains inconclusive72, and neither finasteride nor 
dutasteride have been approved by the Food and Drug Administration for cancer prevention. 
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There has also been much interest in the role of statins for cancer prevention, but the overall 
evidence is largely negative73.  
Conclusions 
Despite its early stage of development, preventive therapy already has made important 
discoveries which have the potential to make useful reductions in cancer incidence. Of these 
low dose aspirin stands out as having the largest potential impact  on the population at large. 
This is because it has a major impact on three common gastrointestinal cancers – colorectal, 
gastric and oesophageal, and potentially provides small reductions in 3 other major cancers – 
lung, breast and prostate. In terms of relative overall importance for cancer prevention tobacco 
cessation remains the most important factor, and Parkin74 have estimated that tobacco use is 
responsible for 19% of all cancers. However they have calculated that no other activity is 
responsible for more than 10% of cancers, and the estimate that between 7-10% of cancers 
could be avoided by taking a daily low dose aspirin for 10 years between ages 50-65y with a 
larger 9-13% reduction for mortality28 makes this a key element of any cancer prevention 
strategy. Other preventive activities such as eating more vegetables, reducing obesity, and 
taking more exercise are much harder to achieve 81, and obtaining the full cancer reduction 
benefit identified from controlling these factors is unrealistic. While we are a long way from 
achieving the full benefit of preventive therapy, widespread use of aspirin is likely to be more 
acceptable,  and other more toxic agents can be targeted to high risk individuals where there is 
a greater possibility of acceptance. Clearly a strategy that uses both approaches is needed. 
 
Several major challenges remain however. Key among these is to find ways to encourage more 
widespread use of agents with established utility. Uptake of tamoxifen in women at high risk 
of breast cancer is only 10% at best and much of this is due to a lack of knowledge and interest 
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in prevention from health professionals. Aspirin has suffered from earlier recommendations 
from professional bodies against using it in the general population75. However these 
recommendations were based on comparing cardiovascular benefits to bleeding risks, and now 
need updating in view of the much larger benefits seen for cancer prevention than for 
cardiovascular disease. These have only appeared more recently, largely due to the fact that 
they were not apparent until after 3-5 years of aspirin use.  
There are several areas where further work is needed to focus the use of prevention agents. Key 
among these is risk assessment. This is less critical for aspirin as benefits are for a range of 
cancers, and we still do not understand the mechanisms behind its cancer prevention effects. 
Knowing these may help to focus use on those most likely to benefit, but a more immediate 
need is to understand who is at greatest risk of bleeding side effects, so that avoidance of use 
or treatment predisposing factors such as helicobacter infection can be employed. For the use 
of anti-oestrogen agents to prevent breast cancer, serious side effects are more common and 
risk in the general population is lower so targeting therapies to high risk individuals is essential 
to achieve a favourable benefit-risk ratio. Classical factors as combined in risk scores76,77, 
mammographic breast density78 and a panel of individual SNPs that are common but 
individually have low predictive power but in combination appear useful79 all are useful in risk 
assessment. Finding the best way to combine these factors to produce a more comprehensive 
risk model is needed. 
A similar need is to find biomarkers which not only accurately predict risk, but also response 
to treatment, as LDL cholesterol and blood pressure provide for cardiovascular disease. 
Changes in mammographic breast density have been shown to predict response to endocrine 
agents both in the preventive80 and adjuvant treatment settings, but 6-12 months of treatment 
is needed to detect this, and earlier markers of effect are desirable. 
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There is still a long list of promising agents that need further investigation. Full scale 
prevention trials are expensive and require long term follow up. They probably are unavoidable 
for agents in which widespread use is proposed, but we need better biomarkers and greater 
understanding of mechanisms to ensure we target the large prevention trials on agents very 
likely to be effective. 
We also need to integrate activities to promote preventive therapy with those to encourage a 
healthy lifestyle. Neither of these alone will eliminate cancer, and adoption of one does not 
obviate the need for the other. In this regard we need to better integrate preventive therapy with 
other activities. Linking it with screening, especially breast screening where women attend a 
dedicated screening centre, is an obvious but undeveloped approach. However, this will require 
specialist staff in the screening clinics to be effective. Consideration of renaming breast 
screening programmes as breast cancer prevention programmes has merit, especially as 
mammographic breast density is an important risk factor which needs to be combined with a 
risk assessment based on family history and other classical risk factors, and possibly including 
a SNP risk score from blood or saliva. Advice from a trained nurse about what can be done to 
lower risk not only for breast cancer but other cancers and diseases is also needed to make this 
effective. 
In addition to developing and publicizing effective agents we also have an obligation to debunk 
claims for ineffective agents. Cancer is such an emotional issue that people can often be misled 
by unsubstantiated claims for prevention or cure and part of a programme for cancer prevention 
needs to also make clear when evidence for an effect is very limited, non-existent or even 
clearly negative. 
Prevention has become an integral part of cardiovascular medicine where risk factors such as 
high cholesterol of hypertension have been raised to the level of diseases in their own right. 
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Although preventive therapy for cancer is still in its early days, we have already identified 
agents which if fully used would have an important impact on incidence and mortality. Because 
of the site specific nature and mechanistic complexity of cancer, progress will be challenging 
but there are already sufficient leads to feel confident that more can be achieved. 
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Table 1. Established methods for cancer prevention 
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effective if before 
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76% reduction of 
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Table 2. Potential common or major side effects of pharmacologic agents considered for cancer 
prevention. 
Agent Side effect Findings 
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Figure 1. Long term effect of tamoxifen on breast cancer prevention in the IBIS-I trial. From 











Figure 2. Impact of aspirin on cancer mortality by scheduled duration of treatment. From 
Rothwell30 et al 2011. 
 
 
 
 
 
 
